

Serdexmethylphenidate, a Prodrug of Dexmethylphenidate and Contained in & R U L XADHD Medication AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), Has Low Relative Potential for Abuse

Three randomized, controlled clinical studies demonstrate long-acting serdexmethylphenidate yielded significantly lower abuse-related effects, fewer stimulant-like adverse events than dexmethylphenidate

Results published in Current Medical Research & Opinion

Boston, MA, June 1, 2022 ±Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced that serdexmethylphenidate 3(xm)-676a.t

fewer stimulant-like adverse events compared to d-MPH. This peer-reviewed finding appears in the May 2022 publication of Current Medical Research & Opinion. AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is the first and only medicine containing SDX and was approved by the U.S. FDA in March 2021 as a once-daily treatment for ADHD symptoms in patients aged 6 years and older.

The studies demonstrate that SDX is associated with significantly lower abuse potential than d-MPH via oral, intranasal, and intravenous routes of administration. These results provide important information to enable

which is a Schedule II therapy, contains 70% SDX (a Schedule IV substance) and 30% d-MPH (a Schedule II substance). Consequently, AZSTARYS provides control of ADHD symptoms rapidly with the immediate-release d-MPH and for an extended duration with SDX while also providing a gradual offset of action. Once-daily AZSTARYS is available in the U.S. in three SDX/immediate-release d-MPH dose strengths of 26.1/5.2 mg, 39.2/7.8 mg, and 52.3/10.4 mg.

³ 7KH VWXGLHV SURILOHG WKH DEXVH SRWHQW LDO RI 6'; U via three administration routes using a rigorous experimental design in recreational stimulant users and analyses that used clinically meaningful assessments. The findings enhance our understanding of the relative abuse

INDICATION

soft tissue breakdown. Carefully observe patients during treatment for digital changes. Further evaluation may be required, including referral.

- x CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Monitor height and weight at appropriate intervals in pediatric patients. Treatment may need to be interrupted in children not growing or gaining weight as expected.

ADVERSE REACTIONS

- x Based on accumulated data from other methylphenidate products, the most common (>5% and twice the rate of placebo) adverse reactions are appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased.

DRUG INTERACTIONS

- x Adjust dosage of antihypertensive drug as needed. Monitor blood pressure.
- x Avoid use of AZSTARYS on the day of surgery if halogenated anesthetics will be used.

For additional safety information, click here for [Prescribing Information](#) and [Medication Guide](#), including BOXED WARNING .

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1 -800-FDA-1088.

About Corium

Corium, Inc., is a commercial-stage biopharmaceutical company that is leading the development and commercialization of CNS therapies that provide clinicians with important new treatment options for patients, their families, and their caregivers. Corium is commercializing two U.S. FDA approved products, ADLARITY®, approved in March 2022, and AZSTARYS. Corium has a robust development pipeline focused on addressing unmet needs in the treatment of patients with CNS conditions. In 1 R Y H P E H U D O O R I & R U L X P ¶ V R X W V W D Q G L Q J V W R F N Z Gurnet Point Capital. For further information, please visit <http://www.corium.com>.

About Gurnet Point Capital

Gurnet Point Capital is a unique healthcare investment platform within the B-Flexion group and led by a team with deep expertise in an industry for which they share a passion, both as investors and senior executives. GPC invests long-term capital and supports entrepreneurs in building a new generation of companies that deliver outsized returns through active ownership. Based in Cambridge, MA, its remit encompasses life sciences and health care focused businesses, with a particular emphasis on businesses that have high growth potential in the product development and commercialization stages of their evolution. With its strategy of driving best in class operational transformation for these businesses, to create social impact while generating significant economic value, GPC is able to deliver differentiated results for

its investors and partners. For more, go to <http://www.gurnetpointcapital.com>.

###

Contact:

Corium, Inc.

Heather Gartman

Gartmanpr@gmail.com

202-413-4226